studi
popul
drawn
mer
referr
hospit
riyadh
saudi
arabia
patient
test
posit
merscov
local
realtim
revers
transcript
pcr
rrtpcr
assay
admit
hospit
august
elig
particip
enrol
patient
provid
inform
written
consent
review
epidemiolog
interview
conduct
time
case
identif
includ
patient
demograph
symptom
histori
relev
exposur
week
onset
patient
death
discharg
perform
comprehens
medic
chart
review
collect
medic
histori
symptom
hospit
daili
inform
regard
symptom
hospit
clinic
cours
treatment
medic
patient
vital
sign
diagnost
test
clinic
outcom
assess
merscov
infect
statu
retrospect
review
data
sourc
avail
contain
inform
clinic
diagnost
test
rrtpcr
request
form
submit
region
test
facil
hospit
copi
correspond
result
hospit
clinic
seri
incomplet
rrtpcr
result
health
electron
surveil
network
nation
platform
report
notifi
diseas
saudi
arabia
merscov
clinic
diagnost
test
perform
urt
lrt
specimen
typic
collect
everi
day
throughout
hospit
healthcar
personnel
collect
lrt
specimen
intub
patient
urt
specimen
otherwis
merscov
result
posit
probabl
neg
avail
cycl
threshold
ct
valu
merscov
upstream
envelop
e
upe
open
read
frame
orf
probabl
find
indic
target
detect
specimen
process
screen
upe
rrtpcr
specimen
posit
rtpcr
confirm
assay
previous
describ
merscov
isol
perform
previous
describ
attempt
full
genom
sequenc
previous
describ
earliest
avail
respiratori
specimen
serum
avail
patient
serum
specimen
suffici
volum
test
use
cdc
serolog
assay
microneutr
mn
assay
spike
pseudoparticl
neutral
assay
vsvmerss
elisa
igspecif
nucleocapsid
n
elisa
igspecif
addit
descript
avail
appendix
defin
ill
onset
first
day
report
symptom
consist
mer
asymptomat
patient
identifi
routin
contact
investig
use
date
first
posit
merscov
test
analyz
data
rel
date
ill
onset
day
patient
classifi
diabet
mellitu
dm
document
medic
histori
dm
patient
multipl
period
hyperglycemia
hospit
random
glucos
read
mgdl
document
medic
histori
dm
consid
possibl
dm
statu
cardiac
diseas
includ
congest
heart
failur
coronari
arteri
diseas
histori
myocardi
infarct
report
isol
hypertens
includ
pulmonari
diseas
includ
chronic
obstruct
pulmonari
diseas
asthma
reactiv
airway
diseas
use
supplement
oxygen
home
renal
diseas
includ
report
chronic
kidney
diseas
secondari
exposur
defin
contact
person
week
ill
onset
primari
exposur
defin
either
report
direct
camel
contact
known
contact
person
retrospect
categor
patient
group
basi
need
supplement
oxygen
ventil
clinic
outcom
group
receiv
room
air
throughout
hospit
group
requir
ventil
support
mechan
nonmechan
surviv
group
requir
ventil
support
die
analyz
durat
detect
merscov
among
survivor
assess
number
day
ill
onset
neg
clinic
respiratori
specimen
test
region
test
facil
base
report
hospit
health
electron
surveil
network
defin
day
merscov
neg
first
consecut
neg
test
discharg
variabl
base
either
urt
lrt
specimen
mildli
ill
patient
provid
lrt
specimen
assess
detect
urt
specimen
compar
sever
group
assess
prolong
merscov
detect
express
time
neg
binari
variabl
patient
time
neg
versu
day
chose
cutoff
reflect
median
time
neg
among
survivor
given
low
number
patient
cohort
also
assess
addit
cutoff
prolong
shed
strengthen
statist
signific
find
versu
day
versu
day
approxim
viral
load
clinic
result
assess
merscov
upe
rrtpcr
ct
valu
determin
region
test
facil
use
ct
valu
lrt
specimen
assess
mechan
ventil
patient
abl
identifi
minimum
ct
valu
peak
rna
level
subset
patient
specimen
submit
cdc
estim
viral
load
basi
upe
ct
valu
ct
valu
upe
test
neg
posit
compar
proport
serum
specimen
detect
antibodi
respons
survivor
patient
die
assess
specimen
collect
day
ill
onset
day
onset
year
summar
patient
characterist
ill
sever
among
survivor
time
merscov
neg
use
fisher
exact
log
rank
test
compar
group
exact
logist
regress
multivari
analysi
compar
antibodi
titer
estim
viral
load
differ
specimen
type
use
spearman
test
correl
data
analyz
use
microsoft
excel
http
productsofficecom
sa
version
http
wwwsascom
august
total
patient
enrol
among
classifi
asymptomat
admiss
report
symptom
remain
room
air
hospit
figur
appendix
figur
appendix
tabl
patient
identifi
contact
trace
healthcar
personnel
hospit
ensur
isol
twenti
patient
requir
ventil
support
bilevel
posit
airway
pressur
bipap
mechan
ventil
die
group
patient
patient
patient
pt
initi
hospit
intub
road
traffic
accid
mer
onset
exclud
analys
regard
sever
clinic
cours
result
merscov
infect
patient
age
rang
year
male
appendix
tabl
twentythre
patient
underli
medic
condit
document
dm
addit
patient
consid
possibl
dm
statu
exhibit
multipl
period
hyperglycemia
random
glucos
read
mgdl
document
histori
dm
death
associ
older
age
p
dm
p
hypertens
p
cardiac
diseas
p
renal
diseas
p
tabl
among
survivor
ventil
support
associ
dm
p
older
age
p
preill
primari
exposur
p
tabl
among
patient
primari
exposur
dm
appendix
tabl
clinic
cours
time
merscov
neg
clinic
respiratori
specimen
depict
accord
date
ill
onset
figur
appendix
tabl
time
admiss
median
day
differ
group
time
merscov
neg
among
survivor
rang
day
day
ill
onset
typic
longer
among
patient
twelv
patient
discharg
day
onset
mildli
ill
patient
hospit
day
onset
pt
describ
previous
durat
hospit
patient
day
durat
intub
day
patient
die
day
onset
common
symptom
admiss
fever
cough
dyspnea
tabl
dyspnea
admiss
associ
sever
outcom
p
among
patient
report
symptom
admiss
mildli
symptomat
hospit
appendix
tabl
among
patient
fever
cough
commonli
report
proport
patient
either
symptom
appear
align
proport
concurr
detect
merscov
clinic
respiratori
specimen
figur
panel
cough
persist
patient
day
merscov
neg
figur
panel
b
chest
radiograph
patient
describ
abnorm
typic
unilater
find
appendix
tabl
oxygen
satur
remain
patient
among
patient
proport
patient
mechan
ventil
appear
align
proport
detect
merscov
lrt
figur
panel
c
patient
pt
underli
pulmonari
diseas
short
period
requir
extend
mechan
ventil
among
patient
merscov
death
figur
panel
merscov
upe
ct
valu
clinic
diagnost
report
depict
figur
merscov
rna
level
urt
patient
peak
first
week
onset
figur
panel
among
patient
die
rna
level
peak
lrt
week
figur
panel
e
rna
level
typic
began
decreas
figur
panel
c
patient
die
neg
probabl
rrtpcr
result
next
assess
characterist
survivor
prolong
merscov
detect
period
basi
clinic
diagnost
report
urt
specimen
tabl
appendix
tabl
patient
reach
neg
day
onset
like
dm
patient
clear
viru
earlier
p
adjust
sever
group
p
tabl
associ
also
observ
patient
reach
neg
day
onset
p
adjust
sever
group
p
appendix
tabl
evid
associ
stronger
patient
dm
possibl
dm
combin
tabl
appendix
tabl
underli
medic
condit
associ
prolong
detect
survivor
prolong
detect
day
also
like
requir
ventil
support
appendix
tabl
signific
adjust
dm
base
respiratori
specimen
submit
cdc
appendix
figur
fullgenom
sequenc
patient
belong
clade
lineag
genbank
access
no
viabl
merscov
isol
urt
specimen
specimen
mildli
ill
patient
pt
collect
day
onset
describ
previous
specimen
collect
day
patient
subsequ
die
pt
cdc
receiv
nonrespiratori
specimen
merscov
test
collect
patient
month
onset
patient
specimen
exclud
specimen
collect
viru
clear
respiratori
tract
fourteen
patient
merscov
rna
detect
whole
blood
serum
stool
urin
figur
appendix
tabl
merscov
rna
detect
whole
blood
serum
patient
copiesml
day
stool
patient
copiesml
day
patient
rnaposit
stool
concurr
gastrointestin
symptom
specimen
limit
merscov
rna
detect
blood
patient
copiesml
stool
copiesml
high
viral
load
detect
whole
blood
serum
patient
reach
high
copiesml
patient
merscov
rna
detect
urin
die
copiesml
patient
chronic
kidney
diseas
attempt
unabl
isol
live
merscov
stool
specimen
urin
specimen
elev
merscov
rna
level
cdc
test
serum
specimen
collect
day
onset
specimen
survivor
specimen
casepati
die
time
onset
collect
differ
patient
group
surviv
median
day
rang
day
die
median
day
rang
day
four
specimen
survivor
collect
year
ill
onset
time
cours
antibodi
respons
shown
patient
figur
appendix
figur
among
casepati
die
detect
neutral
respons
first
week
ill
week
casepati
avail
specimen
detect
antibodi
mn
tabl
notabl
casepati
exhibit
delay
develop
detect
respons
vsvmerss
pseudoparticl
assay
compar
mn
appendix
figur
detect
sspecif
respons
elisa
also
delay
patient
overal
neutral
assay
better
correl
specimen
survivor
patient
die
appendix
figur
survivor
casepati
die
respons
n
selisa
tabl
although
detect
nspecif
respons
preced
sspecif
respons
patient
year
nspecif
respons
wane
patient
test
next
compar
neutral
antibodi
titer
estim
viral
load
serum
specimen
estim
viral
load
respiratori
specimen
collect
day
figur
appendix
figur
among
specimen
detect
antibodi
mn
figur
viral
rna
often
codetect
serum
urt
lrt
specimen
even
beyond
day
onset
antibodi
titer
typic
higher
codetect
serum
p
urt
p
specimen
observ
frequent
among
patient
die
among
surviv
character
merscov
infect
dynam
patient
demograph
underli
medic
condit
exposur
rout
symptom
progress
antibodi
respons
clinic
outcom
find
demonstr
possibl
associ
dm
prolong
merscov
rna
detect
survivor
adjust
sever
preval
dm
high
saudi
arabia
estim
nation
preval
rang
dm
frequent
report
among
mer
casepati
risk
factor
ill
among
primari
exposur
associ
increas
sever
mortal
observ
studi
dm
less
frequent
report
mer
patient
south
korea
associ
increas
sever
set
less
clear
investig
factor
affect
dm
manag
infect
unknown
inform
merscov
detect
antibodi
respons
casepati
die
limit
studi
patient
die
robust
neutral
antibodi
respons
second
third
week
ill
respons
suffici
patient
recoveri
period
week
rna
level
peak
lrt
casepati
suggest
antibodi
might
suffici
viru
clearanc
antibodi
often
codetect
viral
rna
serum
urt
casepati
die
compar
survivor
codetect
antibodi
rna
describ
previous
patient
outcom
six
patient
die
merscov
rna
serum
despit
presenc
neutral
antibodi
rna
urin
detect
merscov
blood
serum
previous
associ
need
supplement
oxygen
need
mechan
ventil
death
although
detect
rna
blood
serum
sever
group
estim
viral
load
might
higher
patient
die
survivor
difficult
assess
statist
limit
specimen
collect
variabl
time
collect
patient
die
rna
level
lrt
decreas
low
undetect
death
suggest
viral
replic
respiratori
tract
might
variabl
indirectli
contribut
outcom
previou
studi
use
mn
test
sspecif
assay
suggest
casepati
die
might
exhibit
delay
antibodi
respons
although
patient
studi
develop
earli
concomit
mn
vsvmerss
pseudoparticl
assay
respons
casepati
die
exhibit
promin
delay
detect
vsvmerss
elisa
respons
compar
mn
find
warrant
investig
might
suggest
mn
assay
target
antibodi
function
beyond
sspecif
viral
entri
although
neutral
assay
target
differ
merscov
strain
variat
exist
within
receptor
bind
site
virus
appendix
figur
compar
virus
viru
strain
use
elisa
emc
differ
aa
unlik
confer
notabl
differ
bind
polyclon
antibodi
respons
character
viru
shed
among
mildli
ill
patient
ie
requir
supplement
oxygen
hospit
might
typic
isol
home
found
rna
level
urt
peak
first
week
ill
among
group
second
week
previous
suggest
although
lrt
specimen
avail
includ
patient
similar
previou
descript
detect
merscov
rna
blood
serum
mildli
ill
patient
also
detect
rna
stool
day
ill
onset
viabl
viru
isol
specimen
type
merscov
rna
report
stool
previous
sever
ill
time
sinc
ill
onset
patient
unknown
replic
intestin
tract
postul
role
pathogenesi
transmiss
remain
unclear
character
symptom
progress
mildli
symptomat
patient
found
fever
cough
present
typic
align
merscov
detect
howev
patient
remain
febril
report
cough
even
viru
clearanc
urt
given
variabl
observ
symptom
progress
merscov
detect
period
test
viral
shed
continu
inform
patient
manag
state
current
world
health
organ
guidanc
investig
sever
limit
first
number
patient
enrol
might
insuffici
detect
associ
especi
adjust
variabl
second
test
data
avail
onset
patient
use
day
onset
merscov
neg
assess
shed
durat
also
exclud
fatal
case
analys
time
death
reflect
shed
durat
mean
factor
associ
predominantli
mortal
assess
prolong
shed
third
presenc
merscov
rna
necessarili
repres
viabl
viru
fourth
serum
specimen
collect
deem
spars
reliabl
assess
antibodi
kinet
patient
level
prolong
shed
dm
detect
merscov
rna
nonrespiratori
specimen
includ
rnaposit
stool
mildli
ill
patient
consid
infect
prevent
control
determin
whether
home
isol
appropri
presenc
detect
antibodi
casepati
die
codetect
antibodi
viral
rna
might
also
implic
develop
vaccin
antibodi
therapeut
find
broaden
understand
merscov
natur
histori
provid
evid
inform
surveil
strategi
diagnost
therapeut
vaccin
develop
clinic
public
health
manag
guidelin
mer
patient
